During the last 2 decades, long-term survival after lung transplantation has significantly improved. However, among the complications related to the continuous administration of immunosuppressive drugs, malignancy plays an important role. We retrospectively revisited our series of patients to report our experience. From January 1991 we performed 134 lung transplantations in 128 recipients (mean age, 33.4 +/- 13.5 years). In all patients the first-line immunosuppressive regimen was based on a calcineurin inhibitor (cyclosporine or tacrolimus), an antimetabolic agent (azathioprine), and steroids. Five patients (4.2%) developed malignancy and the mean time of occurrence after the transplantation was 46.4 +/- 23 months. The mean age was 41 +/- 16 years (P = not significant [ns]). The tumors were as follows: laryngeal cancer (radiotherapy), colon cancer (surgery plus adjuvant chemotherapy), gastric cancer (surgery plus adjuvant chemotherapy), endobronchial non-Hodgkin lymphoma (NHL) (endoscopic resection plus chemoradiotherapy), and cutaneous and visceral Kaposi's sarcoma (KS) (chemotherapy). All patients have reduced the dose of immunosuppressive drugs; in I of them, tacrolimus was changed to rapamycin. Two patients died because of neoplastic dissemination, another 1 due to obliterans bronchiolitis. The 2 patients with NHL and KS are alive at 6 and 9 months, respectively, without signs of recurrence. Malignancies after lung transplantation represent an important problem. A multidisciplinary approach is mandatory to obtain satisfactory results in terms of improved quality of life and long-term survival.

Malignancies following lung transplantation / Anile, Marco; Venuta, Federico; Diso, Daniele; DE GIACOMO, Tiziano; Rendina, Erino Angelo; Rolla, M.; Ruberto, F.; Liparulo, Valeria; Aratari, M. T.; Di Stasio, M.; Ricella, Chiara; Vitolo, Domenico; Longo, F.; Coloni, Giorgio Furio. - In: TRANSPLANTATION PROCEEDINGS. - ISSN 0041-1345. - 39:6(2007), pp. 1983-1984. (Intervento presentato al convegno 30th Congress of the Italian-Society-of-Organ-Transplantation tenutosi a Padova, ITALY nel NOV 30-DEC 02, 2006) [10.1016/j.transproceed.2007.05.036].

Malignancies following lung transplantation

ANILE, MARCO;VENUTA, Federico;DISO, DANIELE;DE GIACOMO, Tiziano;RENDINA, Erino Angelo;F. Ruberto;LIPARULO, Valeria;RICELLA, CHIARA;VITOLO, Domenico;COLONI, Giorgio Furio
2007

Abstract

During the last 2 decades, long-term survival after lung transplantation has significantly improved. However, among the complications related to the continuous administration of immunosuppressive drugs, malignancy plays an important role. We retrospectively revisited our series of patients to report our experience. From January 1991 we performed 134 lung transplantations in 128 recipients (mean age, 33.4 +/- 13.5 years). In all patients the first-line immunosuppressive regimen was based on a calcineurin inhibitor (cyclosporine or tacrolimus), an antimetabolic agent (azathioprine), and steroids. Five patients (4.2%) developed malignancy and the mean time of occurrence after the transplantation was 46.4 +/- 23 months. The mean age was 41 +/- 16 years (P = not significant [ns]). The tumors were as follows: laryngeal cancer (radiotherapy), colon cancer (surgery plus adjuvant chemotherapy), gastric cancer (surgery plus adjuvant chemotherapy), endobronchial non-Hodgkin lymphoma (NHL) (endoscopic resection plus chemoradiotherapy), and cutaneous and visceral Kaposi's sarcoma (KS) (chemotherapy). All patients have reduced the dose of immunosuppressive drugs; in I of them, tacrolimus was changed to rapamycin. Two patients died because of neoplastic dissemination, another 1 due to obliterans bronchiolitis. The 2 patients with NHL and KS are alive at 6 and 9 months, respectively, without signs of recurrence. Malignancies after lung transplantation represent an important problem. A multidisciplinary approach is mandatory to obtain satisfactory results in terms of improved quality of life and long-term survival.
2007
01 Pubblicazione su rivista::01a Articolo in rivista
Malignancies following lung transplantation / Anile, Marco; Venuta, Federico; Diso, Daniele; DE GIACOMO, Tiziano; Rendina, Erino Angelo; Rolla, M.; Ruberto, F.; Liparulo, Valeria; Aratari, M. T.; Di Stasio, M.; Ricella, Chiara; Vitolo, Domenico; Longo, F.; Coloni, Giorgio Furio. - In: TRANSPLANTATION PROCEEDINGS. - ISSN 0041-1345. - 39:6(2007), pp. 1983-1984. (Intervento presentato al convegno 30th Congress of the Italian-Society-of-Organ-Transplantation tenutosi a Padova, ITALY nel NOV 30-DEC 02, 2006) [10.1016/j.transproceed.2007.05.036].
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/233225
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 13
social impact